Therapeutic Solutions International, Inc. announced appointment of Dr. Boris Minev to the Scientific Advisory Board of the Company. Dr. Minev joins other internationally renowned tumor immunologists including Dr. Francesco Marincola, Dr. Santosh Kesari, and Dr. Feng Lin. Dr. Boris Minev is currently the President of Medical and Scientific Affairs at Calidi Biotherapeutics, Inc. in San Diego, CA. Dr. Minev has a stellar track record of successes in the area of cancer immunotherapy, being a developer of Melacine® the first tumor vaccine to obtain regulatory approval. He held a position as the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy, and nanotechnology. Dr. Minev is also an adjunct professor at the Moores UCSD Cancer Center. There, he served previously as Principal Investigator and Director, Laboratory of Tumor Immunology and Immunotherapy, for more than 15 years. Prior to that, Dr. Minev worked in Dr. Steven Rosenberg's Tumor Immunology Section at the Surgery Branch of the National Cancer Institute.